Search results
Showing 121 to 135 of 729 results for diabet*
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)
Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.
View recommendations for HTG165Show all sections
Sections for HTG165
Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)
Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (HTG721)
Evidence-based recommendations on endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. This involves using heat to destroy the lining of the duodenum to encourage a new lining to grow.
View recommendations for HTG721Show all sections
1 Type 2 diabetes: agreeing my blood glucose (HbA1c) target Patient decision aid c NICE 2022. All rights reserved. Subject to Notice of...
Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema (MIB144)
NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
NICE has developed a medtech innovation briefing (MIB) on NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds .
t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes (MIB227)
NICE has developed a medtech innovation briefing (MIB) on t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes .
NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Diabetes: lipid-lowering therapies for secondary prevention of CVD (IND276)
This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Suspected neurological conditions: recognition and referral (NG127)
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
Show all sections
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.